Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: compasstherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $5.00 → $4.00 | Outperform → Market Perform | Leerink Partners |
| 9/16/2024 | $5.00 | Neutral → Buy | Ladenburg Thalmann |
| 1/31/2023 | $8.00 | Buy | Jefferies |
| 1/27/2023 | $9.00 | Buy | Stifel |
| 5/23/2022 | $12.00 | Buy | H.C. Wainwright |
| 3/15/2022 | $7.00 | Buy | Ladenburg Thalmann |
| 1/19/2022 | $10.00 | Buy | B. Riley Securities |
| 12/22/2021 | $5.00 | Outperform | Raymond James |
| 12/20/2021 | $12.00 | Outperform | SVB Leerink |
| 12/15/2021 | $8.00 | Outperform | Wedbush |
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
3 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024. Details are as follows: Stifel 2024 Healthcare ConferenceLocation: New York, NYDate: Monday, November 18, 2024 Time: 3:00pm ETWebcast Link: https://wsw.com/webcast/stifel96/cmpx Jefferies London Healthcare ConferenceLocation: London, UKDate: November 21, 2024Time: 2:00-2:25 PM GMTWebcast Link: https://wsw.com/webcast/jeff315/cmpx Virtual/Replay
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first quarter of 2025.Designing a Phase 2 trial of CTX-009 in combination with chemotherapy in patients with DLL4-positive colorectal cancer (CRC) treated in the second-line setting; trial initiation expected in mid-2025.Identified neural cell adhesion molecule (NCAM or CD56) as a potential biomarker of response to CTX-471 based on data from the Phase 1 trial; planning a Phase 2 trial in patients with tumors expressing NCAM for mid-2025.Fully enrolled the second dosing cohort of the Phase 1 dose-escal
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study. BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Pharmacodynamic and Response Biomarkers in t
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Poster Title: Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody Authors: Kris Sachsenmeier, Niharika Mettu, Marti
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Location: New York, NY Date: Monday, September 9, 2024 Time: 11:00am ETWebcast Link: https://journey.ct.events/ Cantor Global Healthcare Conference Location: New York, NYDate: Tuesday, September 17, 2024Time: 8:35am ET Webcast Link: https://wsw.com/webcast/cantor
Completed enrollment of the 150 patients in the COMPANION-002 Study, a Phase 2/3 trial of CTX-009 (DLL4 and VEGF-A bispecific antibody) plus paclitaxel versus paclitaxel monotherapy in patients with previously treated, unresectable advanced metastatic or recurrent biliary tract cancers (BTC); top-line data expected in the first quarter of 2025.Approved an Investigator Sponsored Trial (IST) of CTX-009 in patients with BTC in the first-line setting.Completed review of encouraging preliminary data from Stage 1 of COMPANION-003, a Phase 2 trial of CTX-009 in patients with advanced colorectal cancer (CRC) treated in the third- and fourth-line settings. Based on the data, designs of a Phase 2 stud
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, an
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers (BTC) Approved an Investigator Sponsored Trial (IST) of CTX-009 in the first-line setting in patients with Biliary Tract Cancer BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it completed enrollment of the planned 150 patients in COMPANION-002, its randomiz
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024. Fireside Chat detailsDate: Wednesday, June 5, 2024 Time: 1:00 – 1:25 PM ETWebcast Link: https://wsw.com/jefferieswebcast/cmpx/ Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clin
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details: Date: May 04, 2022 Time: 8:00 a.m. ET Webcast: Registration Link Replay availability: A replay will be available on the Compass website for 6 months. Abo
NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
EFFECT - Compass Therapeutics, Inc. (0001738021) (Filer)
S-3 - Compass Therapeutics, Inc. (0001738021) (Filer)
10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
ARS - Compass Therapeutics, Inc. (0001738021) (Filer)
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.
Bisker-Leib will continue to be available to the Company as a Senior Consultant for the next 15 months.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $10 price target.
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year.
Gainers Pulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out today. Butterfly Network (NYSE:BFLY) shares moved upwards by 18.15% to $0.93. The company's market cap stands at $193.5 million. As per the press release, Q1 earnings came out today. Compass Therapeutics (NASDAQ:CMPX) stock rose 11.46% to $1.75. The market value of their outstanding shares is at $240.7 million. Sharps Technology (NASDAQ:STSS) shares increased by 9.2% to $0.27. The market value of their outstanding shares is at $4.2 million. Blueprint Medicines (NASDAQ:BPMC) shares moved up
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock rose 10.15% to $0.33. Imunon (NASDAQ:IMNN) shares increased by 7.63% to $1.55. The market value of their outstanding shares is at $14.5 million. Accolade (NASDAQ:ACCD) shares increased by 5.83% to $8.35. The market value of their outstanding shares is at $646.3 million. The company's, Q4 earnings came out yesterday. Prime Medicine (NASDAQ:PRME) shares increased by 5.53% to $4.67. The market value of their outstanding shares is at $560.1 million. ASLAN Pharma (NASDAQ:
Gainers Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 23.04% to $2.83. The company's market cap stands at $3.7 million. Compass Therapeutics (NASDAQ:CMPX) shares rose 21.62% to $1.8. The market value of their outstanding shares is at $247.6 million. Virax Biolabs Group (NASDAQ:VRAX) shares increased by 19.37% to $0.79. The company's market cap stands at $1.8 million. Nuwellis (NASDAQ:NUWE) shares increased by 13.84% to $0.29. The company's market cap stands at $1.9 million. Can Fite Biofarma (AMEX:CANF) stock moved upwards by 12
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 studyTop-line data readout for COMPANION-002, the Company's randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024 BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company's bispecific DLL
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today is pleased to announce the appointment of two new directors to its board. Joining the board of directors are Ellen Chiniara, JD, former Chief Legal Officer of Alexion Pharmaceuticals, and Mary Ann Gray, PhD, President of Gray Strategic Advisors. Ms. Chiniara and Dr. Gray are both global leaders with deep experience in the life sciences and biopharmaceutical industries. "Ellen and Mary Ann bring immediate and significant value to our board. Ellen's expertis
Leerink Partners downgraded Compass Therapeutics from Outperform to Market Perform and set a new price target of $4.00 from $5.00 previously
Ladenburg Thalmann upgraded Compass Therapeutics from Neutral to Buy and set a new price target of $5.00
Jefferies initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $8.00
Stifel initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $9.00
H.C. Wainwright resumed coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00
Ladenburg Thalmann initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $7.00
B. Riley Securities initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $10.00
Raymond James initiated coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $5.00
SVB Leerink initiated coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $12.00
Wedbush initiated coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $8.00